tbuckley/cabot-search huggingface dataset:
NIMG-13. CHARACTERIZATION OF METABOLISM OF PITUITARY TUMORS BY NMR SPECTROSCOPY
Authors: Omkar Ijare, David Baskin, Kumar Pichumani
Journal: Neuro-Oncology (2017)

The pituitary gland controls the entire endocrine system and is responsible for the production and regulation of many critical hormones including GH, ACTH, LH, FSH, TSH, and prolactin. Pituitary tumors are benign growths that mainly remain in the pituitary gland, which may cause variety of symptoms including vision loss and infertility. Metabolome of pituitary tumors are largely unknown. We are reporting ex vivo NMR spectroscopy based metabolomics of two major subtypes of pituitary tumors. Pituitary tumors [LH/FSH = 3; Prolactinoma = 3] were collected from patients undergoing transsphenoidal hypophysectomy, at the Houston Methodist Hospital and were immediately snap-frozen. Tissue samples were extracted in methanol:chloroform (2:1) solvent-mixture. Lyophilized powders from methanol-layer was reconstituted in D2O containing 1.0 mM DSS (internal standard for quantification of metablites), and the residues from chloroform-layer was redissolved in CDCl3 containing 1% TMS. 1H NMR data were collected on a Bruker 600 MHz spectrometer. Pituitary tumor tissue showed the presence of major CNS metabolites: N-acetyl aspartate (NAA), glutamate, glutamine, myo-inositol (mI), and aspartate. Phosphoethanolamine (PE) was predominantly observed in pituitary tumors. Quantitative comparison of various metabolites between these two types of pituitary tumors showed decreased levels of NAA, mI, and PE and elevated levels of glutamate, glutamine, and aspartate in prolactin secreting tumors. Lipid profiles of the above two groups were comparable to each other. Currently, we are recruiting more number of patients to perform a detailed metabolomics analysis of pituitary tumors of various clinical subgroups. The metabolism in pituitary gland was altered due to tumorigenesis. Determination of pituitary metabolome in different clinical types of tumors will help towards better clinical characterization of these tumors. Further, metabolic pathways associated with key metabolites identified in altered pituitary metabolism will be used to develop molecular targets for designing new therapies for treating pituitary tumors.
Enhancing tumor response to targeted chemotherapy through up-regulation of folate receptor α expression induced by dexamethasone and valproic acid
Authors: E. Péraudeau, L. Cronier, A. Monvoisin, P. Poinot, C. Mergault, F. Guilhot, I. Tranoy-Opalinski, B. Renoux, S. Papot, J. Clarhaut
Journal: Journal of Controlled Release (2017)
Sample Size Matters When Drawing Conclusions on Alternate-Day Fasting Diet
Authors: Paola Portillo-Sanchez, Camilo Gonzalez-Velazquez, Leonardo Mancillas-Adame
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Risks Associated With Primary and Redo Carotid Endarterectomy in the Endovascular Era
Authors: Isibor J. Arhuidese, Muhammad Faateh, Besma J. Nejim, Satinderjit Locham, Christopher J. Abularrage, Mahmoud B. Malas
Journal: JAMA Surgery (2017)

<h3>Importance</h3> Clinical experience suggests worse outcomes for redo carotid endarterectomy (CEA) relative to primary CEA. Objective quantification of the excess risk attributable to redo CEA in this era of proliferating endovascular therapy remains to be determined. <h3>Objective</h3> To evaluate the risks of redo CEA relative to primary CEA. <h3>Design, Setting, and Participants</h3> This study was a retrospective analysis of a prospective cohort of patients maintained by the Society for Vascular Surgery in the Vascular Quality Initiative between January 1, 2003, and April 30, 2016. The setting was consecutive patients from academic and community hospitals across the United States. Participants were patients who underwent primary CEA or redo CEA for symptomatic or asymptomatic carotid stenosis. <h3>Exposures</h3> Primary CEA and redo CEA. <h3>Main Outcomes and Measures</h3> Stroke, death, myocardial infarction, stroke or death, and stroke, death, or myocardial infarction at 30 days and 1 year. <h3>Results</h3> There were 64 118 CEAs recorded, including 62 749 primary CEAs (97.9%) (median age, 71 years; 39.5% female) and 1369 redo CEAs (2.1%) (median age, 71 years; 42.2% female). Comparing primary CEA vs redo CEA, the incidence of 30-day stroke was 0.7% vs 1.9% (<i>P</i> &lt; .001) for asymptomatic patients and 1.5% vs 1.4% (<i>P</i> = .77) for symptomatic patients for an overall 0.9% vs 1.8% (<i>P</i> = .002). Incidences were 0.8% vs 1.3% (<i>P</i> = .09) for perioperative myocardial infarction, 0.6% vs 1.4% (<i>P</i> = .003) for death, and 1.5% vs 2.6% (<i>P</i> = .001) for stroke or death. Risk-adjusted 30-day stroke (odds ratio [OR], 2.82; 95% CI, 1.69-4.71;<i>P</i> &lt; .001), death (OR, 2.15; 95% CI, 1.21-3.79;<i>P</i> = .009), and stroke or death (OR, 2.06; 95% CI, 1.32-3.23;<i>P</i> = .002) were higher for redo CEA compared with primary CEA among asymptomatic patients but were similar among symptomatic patients for stroke (OR, 0.79; 95% CI, 0.33-1.95;<i>P</i> = .62), death (OR, 1.32; 95% CI, 0.53-3.26;<i>P</i> = .55), and stroke or death (OR, 0.85; 95% CI, 0.39-1.82;<i>P</i> = .68). Stroke or death at 1 year among asymptomatic patients was higher for redo CEA (hazard ratio [HR], 1.36; 95% CI, 1.08-1.69;<i>P</i> = .009) but was similar among symptomatic patients (HR, 0.94; 95% CI, 0.67-1.31;<i>P</i> = .71). <h3>Conclusions and Relevance</h3> The outcomes of redo CEA and primary CEA fall within the professional guidelines for carotid revascularization. However, redo CEA is associated with a 2.8 times increase in the risk of stroke and a 2.2 times increase in the risk of death compared with primary CEA among asymptomatic patients. There is no significant difference in outcomes among symptomatic patients. These redo CEA and primary CEA results should inform patient and clinician expectations at the point of care.
Un caso di tubercolosi acquisita su un volo a lungo raggio: difficoltà presentate dall'indagine
Authors: A Vassiloyanakopoulos, G Spala, E Mavrou, C Hadjichristodoulou
Journal: Eurosurveillance (1999)

La trasmissione di Mycobacterium tuberculosis da passeggero a passeggero a bordo di un volo aereo e stata riportata nel 1996 (1). In precedenza sono stati pubblicati altri casi, in particolare dai Centers for Disease Control che, quindi, avevano proposto dei criteri per condurre indagini su questo tipo di casi (2). Piu recentemente, nel 1998, l'Organizzazione Mondiale della Sanita (OMS) ha pubblicato le linee guida per questo tipo di indagini, dando particolare rilievo alla durata del volo (superiore alle otto ore), all'infettivita del caso indice e alla prossimita dei soggetti esposti (3).
P3.13-006 Correlation between CT Morphology at the Diagnosis and EGFR Status in Patients with Adenocarcinoma of the Lung
Authors: M. Mencoboni, A. Romani, R. Filiberti, A. Brianti, P. Taveggia, M. Bergaglio, D. Schettini, N. Gandolfo
Journal: Journal of Thoracic Oncology (2017)
Basilar Membranes: Biomimetic Artificial Basilar Membranes for Next‐Generation Cochlear Implants (Adv. Healthcare Mater. 21/2017)
Authors: Jongmoon Jang, Jeong Hun Jang, Hongsoo Choi
Journal: Advanced Healthcare Materials (2017)

Artificial basilar membrane (ABM) is an acoustic transducer that mimics cochlear tonotopy. In article number 1700674, Hongsoo Choi and co-workers demonstrate how mechanical-to-electrical transduction can be implemented by the piezoelectric or triboelectric effect for self-powered devices. The ABMs are currently evolving into practical hearing sensors and will be the key technology that opens up the development of next generation cochlear implants in near future.
NIMG-51. RADIOLOGIC PHENOTYPES ARE TREATMENT SPECIFIC AND ASSOCIATED WITH SURVIVAL - EXPLORATORY ANALYSIS OF EORTC 26101
Authors: Martha Nowosielski, Thierry Gorlia, Inga Harting, Alexander Radbruch, Alba Brandes, Martin J B Taphoorn, Walter Taal, Julien Domont, Ahmed Idbaih, Mario Campone, Paul M Clement, Roger Stupp, Michel Fabbro, Emilie Le Rhun, Andreas von Deimling, Michael Platten, Vassilis Golfinopoulos, Martin Bendszus, Martin van den Bent, Wolfgang Wick
Journal: Neuro-Oncology (2017)

EORTC 26101, a randomized phase III trial in recurrent glioblastoma compared lomustine plus bevacizumab to single agent lomustine. In this exploratory analysis the tumors were radiologically followed and characterized with the objective to investigate whether type of radiologic progression differs between the treatment groups and is related to outcome. Five progression types (PTs) were categorized using an adapted algorithm according to MRI contrast enhancement behavior in T1 and T2-weighted images in 373 patients (lomustine, n=129; combination, n=244). Frequencies of PTs (designated as cT1 relapse, classic T1, T2 diffuse, T2 circumscribed and primary non-responder), time to progression (PFS) and overall survival (OS) were assessed. Frequencies were compared by Wilcoxon rank test, univariate associations of PTs with survival were tested by log-rank test, hazard ratios (HR) with 95% Confidence interval were calculated by Cox model. Except for “classic T1”, frequencies of PTs differed between the treatment arms, with non-enhancing tumor progression (T2 diffuse and T2 circumscribed) being more commonly detected in the combination group. Complete resolution of contrast enhancement (cT1 relapse) during treatment was associated with better survival than mere decrease (classic T1) of contrast enhancement (PFS; HR=0.57 [0.29.;1.11]) and OS; HR=0.42 [0.15;1.18] for lomustine, PFS; HR=0.33 [0.23;0.45] and OS; HR=0.37 [0.26;0.52] for combination group. Progression of glioblastoma can be characterized radiologically. These radiologic phenotypes are influenced by treatment and are associated with differential outcomes. Complete decrease of contrast enhancement during treatment is associated with longer PFS and OS.
La surveillance des IST en Angleterre répond-elle aux exigences du 21e siècle? Évaluation des données dans la région Sud-Ouest
Authors: C Ihekweazu, N Maxwell, S Organ, I Oliver
Journal: Eurosurveillance (2007)

Cette etude evalue la capacite de deux systemes de surveillance des infections sexuellement transmissibles (IST) a fournir des informations pertinentes, exactes et en temps opportun afin de mener a bien des activites de prevention et de controle en Angleterre, sur la base des donnees du Sud-Ouest, la plus grande des neuf regions du pays.
NIMG-57. SURVIVAL ANALYSIS OF GLIOBLASTOMA (GBM) PATIENTS RECEIVING NEURAL STEM CELL (NSC)-MEDIATED TREATMENT USING T1-WEIGHTED DYNAMIC CONTRAST ENHANCED (DCE) MRI
Authors: Prativa Sahoo, Karen Aboody, Margarita Gutova, Massimo D’Apuzzo, Jana Portnow, Behnam Badie, Paul Frankel, Alexander J Annala, Russell Rockne
Journal: Neuro-Oncology (2017)

The aim of this study was to investigate the effect of tissue perfusion on response to neural stem cell (NSC)-mediated enzyme/prodrug gene therapy and overall survival (OS) of patients with recurrent GBM. This retrospective study includes 12 GBM patients who received NSC-mediated tumor localized 5-Flurouracil chemotherapy production in a first-in-human trial. Perfusion parameters including plasma volume (Vp), permeability (Ktrans) and leakage (λtr) were extracted from DCE-MRIs at three time-points; MRI1-start of the treatment, MRI2-end of the treatment, MRI3-one month follow-up. Relative change in perfusion parameters between MRI2 and MRI3 was calculated by Δ=(MRI3–MRI2)/MRI2. Contrast-enhanced tumor volume was computed from T1-weighted post-contrast MRI at each time point. The effect of perfusion parameters on OS was evaluated with Cox regression. Imaging results were compared with histologic evaluation of surgical specimens. Higher ΔVp and Δλtr as continuous measures were associated with worse OS (p<0.01, log-rank). Additionally, the cut-point of ΔVp>1.4 was associated with a median OS of 2 months (95% CI 0.13-NR) versus 13.0 months for ΔVp≤1.4 (95% CI 9.0-NR, p<0.01, log-rank). Δλtr> 0.4 was associated with a median OS of 4.5 months (0.13-NR) versus 14.5 months (9-NR) otherwise (p<0.03). Volume of contrast enhancement did not show any significant correlation. Imaging findings of vessel and cell density agreed with qualitative assessments of surgical specimens. The positive correlation of leakage with OS at MRI2 could be explained by increased diffusion of the prodrug to the NSCs and thus the chemotherapy to the tumor cells. ΔVp and Δλtr effects on OS could be explained by a decrease in vessel density due to increased response to treatment resulting from improved penetration of the prodrug. Our results show the potential value of DCE-MRI parameters to predict survival and may be useful as a measure of treatment response following NSC-mediated therapy.
Incidência dos marcadores virais e evaluação do risco estimado na população de dadores de sangue na Suiça de 1996 a 2003
Authors: C Niederhauser, P Schneider, M Fopp, A Ruefer, G Lévy
Journal: Eurosurveillance (2005)

Entre os riscos conhecidos associados as transfusoes de sangue, a transmissao de virus patogenos e considerada como uma das mais graves, e foram desenvolvidas durante as ultimas duas decadas uma serie de medidas para reduzir-la. Actualmente, tem-se considerado que o risco de transmissao de infeccoes virais atraves de componentes do sangue e muito baixo nos paises desenvolvidos. 
O estudo seguinte analiza, entre 1996 e 2003, a incidencia do VIH, do virus da hepatite B (VHB), e do virus da hepatite C (VHC) em 99% dos dadores de sangue voluntarios dos servicios de transfusao da Cruz Vermelha Suica. Tambem foi estimado o risco destes marcadores virais. Durante este periodo, a taxa de incidencia do VHC nao parou de abaixar, enquanto a incidencia do VIH e do VHB nao diminuiu de maneira significativa. Entre 2001 e 2003, no ultimo periodo calculado, o risco residual estimava-se em 1 por 1.900.000 para o VIH, 1 por 2.200.000 para o VHC, e 1 por 115.000 para o VHB. Estes resultados coincidem com os estudos internacionais, que tem demostrado que entre 1996 e 2003 o risco residual foi mais alto para o VHB que para o VHC e o VIH.
Opioid vs Nonopioid Acute Pain Management in the Emergency Department
Authors: Demetrios N. Kyriacou
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
Authors: Junko Tanizaki, Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba, Yasushi Nakamura, Kimio Yonesaka, Keita Kudo, Hiroyasu Kaneda, Yoshikazu Hasegawa, Kaoru Tanaka, Masayuki Takeda, Akihiko Ito, Kazuhiko Nakagawa
Journal: Journal of Thoracic Oncology (2017)
PUB055 Nodal Status Based on the Anatomical Location or the Number of Lymph Nodes Metastasis
Authors: K. Masai, S. Omura, M. Suzuki, H. Tanaka, S. Kuriyama, H. Sakamaki, K. Kaseda, T. Hishida, T. Ohtsuka, H. Asamura
Journal: Journal of Thoracic Oncology (2017)
NIMG-93. DISCRIMINATION OF CLINICALLY IMPACTFUL TREATMENT RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING BEVACIZUMAB TREATMENT
Authors: Kyle W Singleton, Sandra K Johnston, Andrea Hawkins-Daarud, Cassandra R Rickertsen, Gustavo De Leon, Lauren Kunkel, Scott A Whitmire, Kamala Clark-Swanson, Bernard Bendok, Maciej Mrugala, Alyx Porter, Kristin R Swanson
Journal: Neuro-Oncology (2017)

Clinicians have few effective tools for assessing treatment response in glioblastoma that are predictive of patient outcomes. In previous work, a personalized response metric based on a proliferation-invasion tumor mathematical model, Days Gained, was prognostic for progression-free and overall survival following upfront radiotherapy. In this work, we investigate Days Gained in the recurrent setting for patients receiving bevacizumab (Avastin). We identified 44 patients with recurrent glioblastoma treated with bevacizumab from our clinical research database. Tumor volumes were segmented for T1GD and FLAIR images at two dates prior to treatment and at first imaging follow-up. Tumor growth characteristics from T1GD and FLAIR measurements were used to compute Days Gained response scores in 44 and 39 cases respectively. Days Gained thresholds for discriminating survival following treatment were determined with Kaplan-Meier and Cox Proportional Hazard analysis. Larger Days Gained was associated with better survival from the start of bevacizumab treatment with an optimal threshold of 94.3 Days Gained (p=0.0079, log rank) using T1GD measurements and 155.6 days using FLAIR measurements (p=0.034, log rank). Both thresholds were significant in univariate Cox regression analysis (T1GD: HR=0.382, p=0.011, HR=0.436, FLAIR: p=0.039). T1GD Days Gained remained significant after controlling for age and sex (HR= 0.314, p=0.003) while FLAIR did not (p=0.304). Days Gained was able to discriminate survival in patients receiving bevacizumab treatment in the recurrent setting. The optimal T1GD Days Gained threshold for bevacizumab treatment was similar to prior analyses in patients receiving upfront radiotherapy analysis (94 vs. 78 DG). Combined with our previous results connecting Days Gained to outcome predictions, these findings support the potential for Days Gained to be optimized as a response metric for multiple therapies. Days Gained shows promise as a response metric for bevacizumab treatment and should continue to be evaluated for other glioblastoma therapies.
Mechanisms of macular edema: Beyond the surface
Authors: Alejandra Daruich, Alexandre Matet, Alexandre Moulin, Laura Kowalczuk, Michaël Nicolas, Alexandre Sellam, Pierre-Raphaël Rothschild, Samy Omri, Emmanuelle Gélizé, Laurent Jonet, Kimberley Delaunay, Yvonne De Kozak, Marianne Berdugo, Min Zhao, Patricia Crisanti, Francine Behar-Cohen
Journal: Progress in Retinal and Eye Research (2017)

Macular edema consists of intra- or subretinal fluid accumulation in the macular region. It occurs during the course of numerous retinal disorders and can cause severe impairment of central vision. Major causes of macular edema include diabetes, branch and central retinal vein occlusion, choroidal neovascularization, posterior uveitis, postoperative inflammation and central serous chorioretinopathy. The healthy retina is maintained in a relatively dehydrated, transparent state compatible with optimal light transmission by multiple active and passive systems. Fluid accumulation results from an imbalance between processes governing fluid entry and exit, and is driven by Starling equation when inner or outer blood-retinal barriers are disrupted. The multiple and intricate mechanisms involved in retinal hydro-ionic homeostasis, their molecular and cellular basis, and how their deregulation lead to retinal edema, are addressed in this review. Analyzing the distribution of junction proteins and water channels in the human macula, several hypotheses are raised to explain why edema forms specifically in the macular region. "Pure" clinical phenotypes of macular edema, that result presumably from a single causative mechanism, are detailed. Finally, diabetic macular edema is investigated, as a complex multifactorial pathogenic example. This comprehensive review on the current understanding of macular edema and its mechanisms opens perspectives to identify new preventive and therapeutic strategies for this sight-threatening condition.
OA 13.03 Wide Expression of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1 Negative Human Lung Cancers
Authors: H. Cheng, A. Borczuk, M. Janakiram, X. Ren, J. Lin, A. Assal, B. Halmos, R. Perez-Soler, X. Zang
Journal: Journal of Thoracic Oncology (2017)
OA 12.06 Plasma Genomic Profiling and Outcomes of Patients with MET Exon 14-Altered NSCLCs Treated with Crizotinib on PROFILE 1001
Authors: A. Drilon, J. Clark, J. Weiss, S. Ou, D.R. Camidge, B. Solomon, G. Otterson, L. Villaruz, G. Riely, R. Heist, G. Shapiro, D. Murphy, Y. Liu, S. Wang, T. Usari, K. Wilner, P. Paik
Journal: Journal of Thoracic Oncology (2017)
P3.05-007 Potential of CYFRA 21-1 and CEA to Predict Adjuvant Chemotherapy Benefit in Early-Stage Squamous Cell Lung Cancer
Authors: T. Muley, V. Rolny, Y. He, B. Wehnl, A. Escherich, A. Warth, C. Stolp, M. Schneider, H. Dienemann, M. Meister, F. Herth, F. Dayyani
Journal: Journal of Thoracic Oncology (2017)